Telix Pharmaceuticals Ltd

詳細情報 Telix Pharmaceuticals Ltd 企業名

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.

企業情報

企業コードTLX

会社名Telix Pharmaceuticals Ltd

上場日Nov 15, 2017

最高経営責任者「CEO」Mr. Kevin Richardson

従業員数- -

証券種類Ordinary Share

決算期末- -

本社所在地55 Flemington Road

都市MELBOURNE

証券取引所Xetra

国Australia

郵便番号3051

電話番号61390933855

ウェブサイトhttps://telixpharma.com/

企業コードTLX

上場日Nov 15, 2017

最高経営責任者「CEO」Mr. Kevin Richardson

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Marie McDonald

Non-Executive Director

--

Dr. Paul Schaffer

Chief Technology Officer

--

Mr. Richard Valeix

Group Chief Commercial Officer

--

Mr. James Stonecypher

Group Chief Development Officer

--

Dr. Mark Nelson, Ph.D.

Non-Executive Independent Director

--

Ms. Tiffany P. Olson

Non-Executive Independent Chairman of the Board

--

Dr. Christian P. Behrenbruch, J.D., Ph.D.

Group Chief Executive Officer, Managing Director, Executive Director

--

Mr. Darren Smith, CPA

Group Chief Financial Officer

--

Ms. Genevieve Ryan

Company Secretary

--

Dr. David Cade

Group Chief Medical Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Marie McDonald

Non-Executive Director

--

Dr. Paul Schaffer

Chief Technology Officer

--

Mr. Richard Valeix

Group Chief Commercial Officer

--

Mr. James Stonecypher

Group Chief Development Officer

--

Dr. Mark Nelson, Ph.D.

Non-Executive Independent Director

--

Ms. Tiffany P. Olson

Non-Executive Independent Chairman of the Board

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Aug 23

株主統計

種類

株主統計

比率

Pier Capital, LLC

0.06%

Russell Investments Trust Company

0.02%

Fidelity Management & Research Company LLC

0.01%

Citadel Advisors LLC

0.01%

Driehaus Capital Management, LLC

0.01%

他の

99.89%

株主統計

比率

Pier Capital, LLC

0.06%

Russell Investments Trust Company

0.02%

Fidelity Management & Research Company LLC

0.01%

Citadel Advisors LLC

0.01%

Driehaus Capital Management, LLC

0.01%

他の

99.89%

種類

株主統計

比率

Investment Advisor

0.11%

Research Firm

0.01%

Hedge Fund

0.01%

Investment Advisor/Hedge Fund

0.01%

他の

99.86%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

11

269.45K

0.08%

+265.72K

2025Q1

6

20.71K

0.01%

+16.98K

2024Q4

1

3.73K

0.00%

+3.73K

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Private Advisor Group LLC

10.14K

0%

+10.14K

--

Mar 31, 2025

詳細を見る

9.980USD

Telix Pharmaceuticals Ltd

9.980

概要

企業名

金融

分析